The invention relates to viral particles which are released by mammal cellsafter the infection with the human cytomegalovirus (HCMV). The invention alsorelates to particles whose antigenicity has been optimised by changing theHMCV using genetic engineering. The invention further relates to the use ofsuch particles as a vaccine and to a method for multiplying the HCMV in mammalcells.